TuHURA Biosciences, Inc. (NASDAQ:HURA) Stock Has Consensus Target Price of $9.00 According to Brokerages

TuHURA Biosciences, Inc. (NASDAQ:HURA) has been assigned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation and five have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $9.00.

HURA has been the topic of several recent research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of TuHURA Biosciences in a research report on Friday, July 17th. Citizens Jmp restated a “market outperform” rating and issued a $9.00 target price on shares of TuHURA Biosciences in a research report on Tuesday, August 18th.

Hedge Funds Weigh In On TuHURA Biosciences

Hedge funds and other institutional investors have recently modified their holdings of the company. Squarepoint Ops LLC bought a new position in shares of TuHURA Biosciences during the second quarter valued at approximately $81,000. HighTower Advisors LLC grew its stake in shares of TuHURA Biosciences by 42.5% in the 2nd quarter. HighTower Advisors LLC now owns 30,151 shares of the company’s stock worth $71,000 after buying an additional 8,999 shares during the last quarter. Two Sigma Securities LLC purchased a new stake in shares of TuHURA Biosciences in the 2nd quarter worth approximately $33,000. Hsbc Holdings PLC bought a new position in TuHURA Biosciences during the 2nd quarter valued at approximately $69,000. Finally, Jefferies Financial Group Inc. purchased a new position in TuHURA Biosciences during the second quarter valued at $98,000. 0.62% of the stock is owned by institutional investors.

TuHURA Biosciences Stock Up 1.6%

Shares of NASDAQ HURA opened at $1.96 on Wednesday. The company has a debt-to-equity ratio of 0.20, a current ratio of 0.18 and a quick ratio of 0.18. The stock has a market capitalization of $124.91 million, a PE ratio of -3.63 and a beta of -0.21. TuHURA Biosciences has a one year low of $0.41 and a one year high of $3.43. The business’s fifty day moving average price is $2.10 and its 200-day moving average price is $2.22.

TuHURA Biosciences (NASDAQ:HURA) last announced its quarterly earnings results on Friday, August 14th. The company reported ($0.14) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.01. On average, equities research analysts anticipate that TuHURA Biosciences will post -0.55 EPS for the current year.

TuHURA Biosciences Company Profile

TuHURA Biosciences, Inc (NASDAQ:HURA) is a clinical-stage biotechnology company focused on developing therapies designed to overcome immune suppression in the tumor microenvironment and improve responses to cancer treatment. The company’s research is centered on immuno-oncology approaches intended to stimulate both innate and adaptive immune responses against tumors.

TuHURA’s lead program, IFx-2, is an investigational intratumoral immunotherapy and cancer vaccine candidate designed to reprogram the tumor environment and promote an immune response.